Skip to main content
. 2021 May 10;14:1785–1795. doi: 10.2147/IJGM.S300517

Table 2.

Comparison of Characteristics Between Treatment Non-Effective Group and Effective Group

n= 132 Non-Effective Group Effective Group
n = 49 n = 83
Age ± SD 58.5 ± 19.1 56.4 ± 18.4
Female (%) 34 (69.4%) 54 (65.1%)
BMI ± SD 24.2 ± 3.8 23.6 ± 3.6
No. of smoker patients (%) 6 (12.2%) 18 (21.7%)
Blood tests
 Albumin ± SD (g/dL) 4.26 ± 0.33 4.18 ± 0.33
 Creatinine ± SD (mg/dL) 0.71 ± 0.12 0.71 ± 0.16
 HbA1c ± SD (%) 5.47 ± 0.30 5.46 ± 0.34
 3HB ± SD (μmol/L) before treatment (%) 49.0 ± 46.8 81.0 ± 62.0 ***
No. of patients with high-3HB# before treatment (%) 3 (6.1%) 37 (44.6%) ***
Psychological tests
 CES-D ± SD 19.6 ± 12.4 23.7 ± 14.4
 STAI-state ± SD 48.8 ± 12.9 50.3 ± 10.5
 STAI-trait ± SD 50.8 ± 11.5 52.5 ± 11.3
Current use of benzodiazepines (%) 17 (34.7%) 27 (32.5%)
Physical complaints and episodes
 Fatigue (%) 18 (36.7%) 42 (50.6%)
 Dizziness or vertigo (%) 12 (24.5%) 21 (25.3%)
 Headache (%) 11 (22.5%) 34 (41.1%)*
 Non-headache pain (%) 12 (25.0%) 33 (40.1%)
 Numbness (%) 11 (22.5%) 13 (15.7%)
 Nausea (%) 9 (18.4%) 14 (16.9%)
 Chest tightness (%) 11 (22.5%) 13 (15.7%)
 Palpitation (%) 11 (22.5%) 15 (18.1%)
 Chronic cough or globus syndrome (%) 12 (25.0%) 16 (19.3%)
 Breathlessness (%) 3 (6.1%) 5 (6.0%)
Psychological complaints and episodes
 Anorexia (%) 13 (26.5%) 23 (27.7%)
 Insominia (%) 33 (67.4%) 54 (65.1%)
 Diminished motivation (%) 28 (57.1%) 57 (68.7%)
 Suicidal ideation (%) 2 (4.1%) 24 (29.0%) ***
The ultimate psychiatric diagnosis $
 Mood disorder (%) 12 (24.5%) 36 (43.4%) *
  <Major depression (%)> 7 (15.3%) 23 (27.7%)
 Anxiety disorder (%) 8 (16.3%) 13 (15.7%)
 Somatoform disorder (%) 36 (73.5%) 43 (51.8%)*

Notes: *Significance compared with non-effective group (*p<0.05, ***p<0.001). #High-3HB: ≥80 μmol/L. $Diagnosis is overlapped in some patients.